Search

Your search keyword '"MARCATILI M."' showing total 95 results
Start Over Author "MARCATILI M."
95 results on '"MARCATILI M."'

1. Comparing the COVID-19-related PTSD symptoms between psychiatric patients and healthy subjects: an observational retrospective study from Northern Italy

Author

Caldiroli, A, Tagliabue, I, Turco, M, Capuzzi, E, Fortunato, A, Tringali, A, Montana, C, Maggioni, L, Pellicioli, C, Sibilla, M, Marcatili, M, Crespi, G, Colmegna, F, Buoli, M, Clerici, M, Caldiroli A., Tagliabue I., Turco M., Capuzzi E., Fortunato A., Tringali A., Montana C., Maggioni L., Pellicioli C., Sibilla M., Marcatili M., Crespi G., Colmegna F., Buoli M., Clerici M., Caldiroli, A, Tagliabue, I, Turco, M, Capuzzi, E, Fortunato, A, Tringali, A, Montana, C, Maggioni, L, Pellicioli, C, Sibilla, M, Marcatili, M, Crespi, G, Colmegna, F, Buoli, M, Clerici, M, Caldiroli A., Tagliabue I., Turco M., Capuzzi E., Fortunato A., Tringali A., Montana C., Maggioni L., Pellicioli C., Sibilla M., Marcatili M., Crespi G., Colmegna F., Buoli M., and Clerici M.

Abstract

COVID-19 pandemic had a great impact on mental health, both in the general population and psychiatric patients. Little is known about the difference between these two populations in perceiving the pandemic as a traumatic event. The aim of the study was to compare psychiatric patients and healthy controls (HC) in terms of change over time of post-traumatic (PTSD) symptoms. Demographic and clinical variables were collected. Impact of Event Scale Revised (IES-R) scores were registered at T1 as lockdown period (March–April 2020) and T2 as restarting (May–June 2020). Descriptive analyses and linear regression models were performed. A total of 166 outpatients and 57 HC were recruited. Time (F = 15.76; p < 0.001) and diagnosis (F = 4.94; p < 0.001) had a significant effect on the change of IES-R scores, which resulted T1 > T2 (p < 0.001), except for subjects affected by Obsessive-Compulsive Disorder (OCD). Overall, IES-R scores were < in patients than in HC (p = 0.02), particularly in the schizophrenia (SKZ) subgroup (p < 0.001). IES-R scores of subjects with personality disorders (PDs) resulted to be > HC, although not statistically significant. The lockdown period was perceived as more traumatic than the reopening phase by both groups, with the exception of OCD patients, probably because of the clinical worsening associated with the urge of control against risks of contamination. Overall, HC reported more PTSD symptoms than psychiatric patients did, particularly SKZ ones. PD patients, in contrast, may be more vulnerable to PTSD symptoms probably as a result of poor coping skills. Together with OCD patients, subjects with PDs may need closer monitoring during the different phases of the pandemic. Trial Registration: ClinicalTrials.gov Identifier: NCT04694482.

Published
2023

2. Clinical Markers of Panic and Generalized Anxiety Disorder: Overlapping Symptoms, Different Course and Outcome

Author

Caldiroli, A, Colzani, L, Capuzzi, E, Quitadamo, C, La Tegola, D, Surace, T, Russo, S, Capetti, M, Leo, S, Tringali, A, Marcatili, M, Zanelli Quarantini, F, Colmegna, F, Dakanalis, A, Buoli, M, Clerici, M, Caldiroli A., Colzani L., Capuzzi E., Quitadamo C., La Tegola D., Surace T., Russo S., Capetti M., Leo S., Tringali A., Marcatili M., Zanelli Quarantini F., Colmegna F., Dakanalis A., Buoli M., Clerici M., Caldiroli, A, Colzani, L, Capuzzi, E, Quitadamo, C, La Tegola, D, Surace, T, Russo, S, Capetti, M, Leo, S, Tringali, A, Marcatili, M, Zanelli Quarantini, F, Colmegna, F, Dakanalis, A, Buoli, M, Clerici, M, Caldiroli A., Colzani L., Capuzzi E., Quitadamo C., La Tegola D., Surace T., Russo S., Capetti M., Leo S., Tringali A., Marcatili M., Zanelli Quarantini F., Colmegna F., Dakanalis A., Buoli M., and Clerici M.

Abstract

Generalized Anxiety Disorder (GAD) and Panic Disorder (PD) share underlying neurobiological mechanisms and several clinical features which, with medical comorbidities, may increase misdiagnosis and delay proper treatment. The aim of the study was to evaluate the association between clinical/socio-demographic markers and GAD/PD diagnosis. Outpatients (N = 290) with PD or GAD were identified in mental health services in Monza and Milan (Italy). Descriptive analyses and a binary logistic regression model were performed. Post-onset psychiatric (p = 0.05) and medical (p = 0.02) multiple co-morbidities were associated with GAD; treatment with selective serotonin reuptake inhibitors (SSRIs) was associated with PD, while GAD diagnosis was associated with treatment with atypical antipsychotics or GABAergic drugs (p = 0.03), as well as psychodynamic psychotherapy (p < 0.01). Discontinuation of the last pharmacological treatment was associated with GAD diagnosis rather than the PD one (p = 0.02). GAD patients may have a worse prognosis than PD patients because of more frequent multiple co-morbidities, relapses and poorer treatment compliance. The different treatment approaches were consistent with the available literature, while the association between GAD and psychodynamic psychotherapy is an original finding of our study. Further studies on larger samples are necessary to better characterize clinical factors associated with GAD or PD.

Published
2023

3. Management of COVID-19 Infection in a Psychiatric Long-term Care Rehabilitation Facility: Update From an Italian Experience

Author

Nava, R, Don, P, Zanvit, F, Marcatili, M, Capuzzi, E, Colmegna, F, Clerici, M, Nava R., Don P. W., Zanvit F. G., Marcatili M., Capuzzi E., Colmegna F., Clerici M., Nava, R, Don, P, Zanvit, F, Marcatili, M, Capuzzi, E, Colmegna, F, Clerici, M, Nava R., Don P. W., Zanvit F. G., Marcatili M., Capuzzi E., Colmegna F., and Clerici M.

Abstract

After more than a year since publication of the report "Prevention Plan for COVID-19 in a Psychiatric Long- term Care Rehabilitation Facility: An Italian Experience" in the PCC, we would like to address the evolution of the clinical and organizational management of the COVID pandemic in this psychiatric facility and its outcomes.

Published
2023

4. Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports

Author

Marcatili, M, Borgonovo, R, Cimminiello, N, Cornaggia, R, Casati, G, Pellicioli, C, Maggioni, L, Motta, F, Redaelli, C, Ledda, L, Pozzi, F, Krivosova, M, Pagano, J, Nava, R, Colmegna, F, Dakanalis, A, Caldiroli, A, Capuzzi, E, Benatti, B, Dell’Osso, B, Bertola, F, Villa, N, Piperno, A, Ippolito, S, Appollonio, I, Sala, C, Conti, L, Clerici, M, Marcatili M., Borgonovo R., Cimminiello N., Cornaggia R. D., Casati G., Pellicioli C., Maggioni L., Motta F., Redaelli C., Ledda L., Pozzi F. E., Krivosova M., Pagano J., Nava R., Colmegna F., Dakanalis A., Caldiroli A., Capuzzi E., Benatti B., Dell’Osso B., Bertola F., Villa N., Piperno A., Ippolito S., Appollonio I., Sala C., Conti L., Clerici M., Marcatili, M, Borgonovo, R, Cimminiello, N, Cornaggia, R, Casati, G, Pellicioli, C, Maggioni, L, Motta, F, Redaelli, C, Ledda, L, Pozzi, F, Krivosova, M, Pagano, J, Nava, R, Colmegna, F, Dakanalis, A, Caldiroli, A, Capuzzi, E, Benatti, B, Dell’Osso, B, Bertola, F, Villa, N, Piperno, A, Ippolito, S, Appollonio, I, Sala, C, Conti, L, Clerici, M, Marcatili M., Borgonovo R., Cimminiello N., Cornaggia R. D., Casati G., Pellicioli C., Maggioni L., Motta F., Redaelli C., Ledda L., Pozzi F. E., Krivosova M., Pagano J., Nava R., Colmegna F., Dakanalis A., Caldiroli A., Capuzzi E., Benatti B., Dell’Osso B., Bertola F., Villa N., Piperno A., Ippolito S., Appollonio I., Sala C., Conti L., and Clerici M.

Abstract

The advent of intra-nasal esketamine (ESK), one of the first so called fast-acting antidepressant, promises to revolutionize the management of treatment resistant depression (TRD). This NMDA receptor antagonist has proven to be rapidly effective in the short- and medium-term course of the illness, revealing its potential in targeting response in TRD. Although many TRD ESK responders are able to achieve remission, a considerable portion of them undergo a metamorphosis of their depression into different clinical presentations, characterized by instable responses and high recurrence rates that can be considered closer to the concept of Difficult to Treat Depression (DTD) than to TRD. The management of these DTD patients usually requires a further complex multidisciplinary approach and can benefit from the valuable contribution of new personalized medicine tools such as therapeutic drug monitoring and pharmacogenetics. Despite this, these patients usually come with long and complex previous treatments history and, often, advanced and sophisticated ongoing pharmacological schemes that can make the finding of new alternative options to face the current recurrences extremely challenging. In this paper, we describe two DTD patients—already receiving intranasal ESK but showing an instable course—who were clinically stabilized by the association with minocycline, a semisynthetic second-generation tetracycline with known and promising antidepressant properties.

Published
2022

5. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression

Author

Martinotti, G., Dell'Osso, B., Dilorenzo, G., Maina, G., Bertolino, A., Clerici, M., Barlati, S., Rosso, G., Dinicola, M., Marcatili, M., D'Andrea, G., Cavallotto, C., Chiappini, S., Defilippis, S., Nicolo, G., Defazio, P., Andriola, I., Zanardi, R., Nucifora, D., Dimauro, S., Bassetti, R., Pettorruso, M., Mcintyre, R. S., Sensi, S. L., di Giannantonio, M., Vita, A., Baldacci, G., Belletti, S., Bellomo, A., Benatti, B., Carminati, M., Carullo, R., de Berardis, D., de Filippis, R., Chiaie, R. D., di Carlo, F., Di Petta, G., Galluzzo, A., Giorgelli, V., Lombardozzi, G., Martiadis, V., Mattei, C., Mosca, A., Niolu, C., Olivola, M., Percudani, M., Pepe, M., Rossi, E., Scardigli, M. I., Tati, F., Valchera, A., and Vismara, M.

Subjects
Psychiatry and Mental health, bipolar depression, esketamine, pharmacological treatment, rapid-acting antidepressant, treatment-resistant depression, TRD, glutamate, mood disorders, Biological Psychiatry, real-world study
Published
2023

8. Consultation psychiatry in COVID-19 patients: Lopinavir/ritonavir interactions with main psychiatric drugs

Author

Marcatili, M, Stefana, A, Colmegna, F, di Giacomo, E, D'Amico, E, Capuzzi, E, Dakanalis, A, Clerici, M, Marcatili M., Stefana A., Colmegna F., di Giacomo E., D'Amico E., Capuzzi E., Dakanalis A., Clerici M., Marcatili, M, Stefana, A, Colmegna, F, di Giacomo, E, D'Amico, E, Capuzzi, E, Dakanalis, A, Clerici, M, Marcatili M., Stefana A., Colmegna F., di Giacomo E., D'Amico E., Capuzzi E., Dakanalis A., and Clerici M.

Published
2021

9. Augmentative pharmacological strategies in treatment‐resistant major depression: A comprehensive review

Author

Caldiroli, A, Capuzzi, E, Tagliabue, I, Capellazzi, M, Marcatili, M, Mucci, F, Colmegna, F, Clerici, M, Buoli, M, Dakanalis, A, Caldiroli A., Capuzzi E., Tagliabue I., Capellazzi M., Marcatili M., Mucci F., Colmegna F., Clerici M., Buoli M., Dakanalis A., Caldiroli, A, Capuzzi, E, Tagliabue, I, Capellazzi, M, Marcatili, M, Mucci, F, Colmegna, F, Clerici, M, Buoli, M, Dakanalis, A, Caldiroli A., Capuzzi E., Tagliabue I., Capellazzi M., Marcatili M., Mucci F., Colmegna F., Clerici M., Buoli M., and Dakanalis A.

Abstract

Treatment resistant depression (TRD) is associated with poor outcomes, but a consensus is lacking in the literature regarding which compound represents the best pharmacological augmentation strategy to antidepressants (AD). In the present review, we identify the available literature regarding the pharmacological augmentation to AD in TRD. Research in the main psychiatric databases was performed (PubMed, ISI Web of Knowledge, PsychInfo). Only original articles in English with the main topic being pharmacological augmentation in TRD and presenting a precise definition of TRD were included. Aripiprazole and lithium were the most investigated molecules, and aripiprazole presented the strongest evidence of efficacy. Moreover, olanzapine, quetiapine, cariprazine, risperidone, and ziprasidone showed positive results but to a lesser extent. Brexpipra-zole and intranasal esketamine need further study in real‐world practice. Intravenous ketamine presented an evincible AD effect in the short‐term. The efficacy of adjunctive ADs, antiepileptic drugs, psychostimulants, pramipexole, ropinirole, acetyl‐salicylic acid, metyrapone, reserpine, testos-terone, T3/T4, naltrexone, SAMe, and zinc cannot be precisely estimated in light of the limited available data. Studies on lamotrigine and pindolol reported negative results. According to our results, aripiprazole and lithium may be considered by clinicians as potential effective augmentative strategies in TRD, although the data regarding lithium are somewhat controversial. Reliable conclusions about the other molecules cannot be drawn. Further controlled comparative studies, standardized in terms of design, doses, and duration of the augmentative treatments, are needed to formulate definitive conclusions.

Published
2021

10. Delirium in the 'young' covid-19 patient (<65 years): Preliminary clinical indications

Author

DI GIACOMO, E, Colmegna, F, Santorelli, M, Pessina, R, D'Amico, E, Marcatili, M, Dakanalis, A, Pavone, F, Fagiolini, A, Clerici, M, DI GIACOMO E., COLMEGNA F., SANTORELLI M., PESSINA R., D'AMICO E., MARCATILI M., DAKANALIS A., PAVONE F., FAGIOLINI A., CLERICI Massimo., DI GIACOMO, E, Colmegna, F, Santorelli, M, Pessina, R, D'Amico, E, Marcatili, M, Dakanalis, A, Pavone, F, Fagiolini, A, Clerici, M, DI GIACOMO E., COLMEGNA F., SANTORELLI M., PESSINA R., D'AMICO E., MARCATILI M., DAKANALIS A., PAVONE F., FAGIOLINI A., and CLERICI Massimo.

Abstract

Delirium is a phenomenon classified within neuro-cognitive disorders in the DSM-5. It has several etiologies and it is often lethal. This contribute aims at analyzing clinical characteristics and diagnostic possibilities of delirium in patients affected by covid-19. Furthermore, some preliminary recommendations on the use of psychopharmacological treatment of delirium and their interactions with main drugs used to treat covid-19 are given, with a special attention to comorbidities like in immunocompromised patients, in those affected by diabetes and cancer, in pregnant women or in addicted clients.

Published
2021

11. Long-term efficacy of intranasal esketamine in treatment-resistant major depression: A systematic review

Author

Capuzzi, E, Caldiroli, A, Capellazzi, M, Tagliabue, I, Marcatili, M, Colmegna, F, Clerici, M, Buoli, M, Dakanalis, A, Capuzzi E., Caldiroli A., Capellazzi M., Tagliabue I., Marcatili M., Colmegna F., Clerici M., Buoli M., Dakanalis A., Capuzzi, E, Caldiroli, A, Capellazzi, M, Tagliabue, I, Marcatili, M, Colmegna, F, Clerici, M, Buoli, M, Dakanalis, A, Capuzzi E., Caldiroli A., Capellazzi M., Tagliabue I., Marcatili M., Colmegna F., Clerici M., Buoli M., and Dakanalis A.

Abstract

Esketamine (ESK) has been approved as a rapid-acting intranasal treatment for treatment-resistant depression (TRD). Although existing studies have investigated the efficacy of ESK in the 4-week induction phase, our knowledge about long-term ESK efficacy remains poor. The aim of this systematic review was to summarize the available data on long-term ESK efficacy for TRD. A systematic search was performed including articles in English, up to 31 March 2021. The search found 7 relevant studies, involving 1024 adult TRD patients. Continuing treatment with ESK after the 4-week induction phase may be associated with stable efficacy in relapse prevention among TRD pa-tients. Conversely, the long-term antidepressant effectiveness upon discontinuation of ESK might be limited, although data from three studies had a moderate to high risk of bias. Overall, the results on the effectiveness of this compound in the long term are mixed. According to our findings, ESK treatment should be continued following the induction phase to reach a stable efficacy in relapse prevention, while the long-term antidepressant and anti-suicidal effects of ESK after discontinuation are inconsistent. Currently, the level of proof of ESK efficacy in long-term TRD treatment remains low and more RCTs with larger sample sizes and active comparators are needed.

Published
2021

12. Comparing the COVID-19-related PTSD symptoms between psychiatric patients and healthy subjects: an observational retrospective study from Northern Italy

Author

Caldiroli, A, primary, Tagliabue, I, additional, Turco, M, additional, Capuzzi, E, additional, Fortunato, A, additional, Tringali, A, additional, Montana, C, additional, Maggioni, L, additional, Pellicioli, C, additional, Sibilla, M, additional, Marcatili, M, additional, Crespi, G, additional, Colmegna, F, additional, Buoli, M, additional, and Clerici, M, additional

Published
2022
Full Text
View/download PDF

13. The psychopathological impact of the SARS-CoV-2 epidemic on subjects suffering from different mental disorders: An observational retrospective study

Author

Caldiroli, A, Capuzzi, E, Tringali, A, Tagliabue, I, Turco, M, Fortunato, A, Sibilla, M, Montana, C, Maggioni, L, Pellicioli, C, Marcatili, M, Nava, R, Crespi, G, Colmegna, F, Buoli, M, Clerici, M, Caldiroli, A, Capuzzi, E, Tringali, A, Tagliabue, I, Turco, M, Fortunato, A, Sibilla, M, Montana, C, Maggioni, L, Pellicioli, C, Marcatili, M, Nava, R, Crespi, G, Colmegna, F, Buoli, M, and Clerici, M

Abstract

SARS-CoV-2 infection causes a pulmonary disease (COVID-19) which spread worldwide generating fear, anxiety, depression in the general population as well as among subjects affected by mental disorders. Little is known about which different psychopathological changes the pandemic caused among individuals affected by different psychiatric disorders, which represents the aim of the present study. Specific psychometric scales were administered at three time points: T0 as outbreak of pandemic, T1 as lockdown period, T2 as reopening. Descriptive analyses and linear regression models were performed. A total of 166 outpatients were included. Overall, psychometric scores showed a significant worsening at T1 with a mild improvement at T2. Only psychopathology in schizophrenia (SKZ) patients and obsessive-compulsive (OC) symptoms did not significantly improve at T2. Subjects affected by personality disorders (PDs) resulted to be more compromised in terms of general psychopathology than depressed and anxiety/OC ones, and showed more severe anxiety symptoms than SKZ patients. In conclusion, subjects affected by PDs require specific clinical attention during COVID-19 pandemic. Moreover, the worsening of SKZ and OC symptoms should be strictly monitored by clinicians, as these aspects did not improve with the end of lockdown measures. Further studies on larger samples are needed to confirm our results. ClinicalTrials.gov Identifier: NCT04694482

Published
2022

14. [Delirium in the 'young' covid-19 patient (65 years): preliminary clinical indications]

Author

DI GIACOMO E., COLMEGNA F., SANTORELLI M., PESSINA R., D'AMICO E., MARCATILI M., DAKANALIS A., PAVONE F., FAGIOLINI A., CLERICI Massimo., DI GIACOMO, E, Colmegna, F, Santorelli, M, Pessina, R, D'Amico, E, Marcatili, M, Dakanalis, A, Pavone, F, Fagiolini, A, and Clerici, M

Subjects
Pregnancy, Addiction, COVID-19, Delirium, Humans, Drug Interactions, Heart disease, Immunocompromission, Middle Aged, Diabete, Cancer, COVID-19 Drug Treatment
Abstract

Delirium is a phenomenon classified within neuro-cognitive disorders in the DSM-5. It has several etiologies and it is often lethal. This contribute aims at analyzing clinical characteristics and diagnostic possibilities of delirium in patients affected by covid-19. Furthermore, some preliminary recommendations on the use of psychopharmacological treatment of delirium and their interactions with main drugs used to treat covid-19 are given, with a special attention to comorbidities like in immunocompromised patients, in those affected by diabetes and cancer, in pregnant women or in addicted clients.

Published
2021

17. Human induced pluripotent stem cells technology in treatment resistant depression: novel strategies and opportunities to unravel ketamine's fast-acting antidepressant mechanisms

Author

Marcatili, M, Sala, C, Dakanalis, A, Colmegna, F, D'Agostino, A, Gambini, O, Dell'Osso, B, Benatti, B, Conti, L, Clerici, M, Marcatili, Matteo, Sala, Carlo, Dakanalis, Antonios, Colmegna, Fabrizia, D'Agostino, Armando, Gambini, Orsola, Dell'Osso, Bernardo, Benatti, Beatrice, Conti, Luciano, Clerici, Massimo, Marcatili, M, Sala, C, Dakanalis, A, Colmegna, F, D'Agostino, A, Gambini, O, Dell'Osso, B, Benatti, B, Conti, L, Clerici, M, Marcatili, Matteo, Sala, Carlo, Dakanalis, Antonios, Colmegna, Fabrizia, D'Agostino, Armando, Gambini, Orsola, Dell'Osso, Bernardo, Benatti, Beatrice, Conti, Luciano, and Clerici, Massimo

Abstract

Approximately 30% of Major Depressive Disorder (MDD) patients develop treatment-resistant depression (TRD). Among the different causes that make TRD so challenging in both clinical and research contexts, major roles are played by the inadequate understanding of MDD pathophysiology and the limitations of current pharmacological treatments. Nevertheless, the field of psychiatry is facing exciting times. Combined with recent advances in genome editing techniques, human induced pluripotent stem cell (hiPSC) technology is offering novel and unique opportunities in both disease modelling and drug discovery. This technology has allowed innovative disease-relevant patient-specific in vitro models to be set up for many psychiatric disorders. Such models hold great potential in enhancing our understanding of MDD pathophysiology and overcoming many of the well-known practical limitations inherent to animal and post-mortem models. Moreover, the field is approaching the advent of (es)ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, claimed as one of the first and exemplary agents with rapid (in hours) antidepressant effects, even in TRD patients. Although ketamine seems poised to transform the treatment of depression, its exact mechanisms of action are still unclear but greatly demanded, as the resulting knowledge may provide a model to understand the mechanisms behind rapid-acting antidepressants, which may lead to the discovery of novel compounds for the treatment of depression. After reviewing insights into ketamine's mechanisms of action (derived from preclinical animal studies) and depicting the current state of the art of hiPSC technology below, we will consider the implementation of an hiPSC technology-based TRD model for the study of ketamine's fast acting antidepressant mechanisms of action.

Published
2020

18. Esigenze Strategiche nella Città Metropolitana di Roma

Author

Filippucci, E, Elisei, P, de Roo Joep, Sept, A, Llop, C, Batunova, E, Dimitriu, S, Del Piano Alessandro, Pratt, A, Apeil Muller Mirelle, Marcatili, M, Prezioso, M, Montino, E, Martines, R, Marini, N, Ombuen, S, Ginocchini, G, Donato, V, Tortoriello, F, and Leodori, D

Subjects
Strategic Planning, EU, Metropolitan area, sustainable development, sustainable development, Settore M-GGR/02 - Geografia Economico-Politica, Pianificazione Strategica, UE, area metropolitana, sviluppo sostenibile, sviluppo sostenibile, Metropolitan area, Pianificazione Strategica, area metropolitana, UE, EU, Strategic Planning
Published
2016

22. Magnetic resonance imaging‐guided injection of platelet‐rich plasma for treatment of an insertional core lesion of the deep digital flexor tendon within the foot of a horse.

Author

Marcatili, M., Marshall, J., and Voute, L.

Subjects
*PLATELET-rich plasma, *FLEXOR tendons, *TISSUE wounds, *DISEASES, *THERAPEUTICS
Abstract

Summary: Definitive diagnosis of a deep digital flexor tendon insertional lesion within the right fore foot was made by magnetic resonance imaging (MRI) examination and the lesion subsequently treated by injection with platelet‐rich plasma. MRI was used to guide positioning of the needle to achieve highly accurate injection. The volume injected was found to approximate the calculated lesion volume. On the basis of experience with this case, MRI‐guided injection of insertional deep digital flexor tendon lesions of the foot of horses under general anaesthesia is practicable. This technique is likely to be more accurate than the other techniques described (computed tomography, ultrasonography) and carries no risk of exposure to radiation (radiography). [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

28. Socio-demographic and clinical characterization of patients with obsessive-compulsive tic-related disorder (OCTD): An Italian multicenter study

Author

Osso, B., Beatrice Benatti, Hollander, E., Zohar, J., Osso, L., Fineberg, N. A., Marcatili, M., Rigardetto, S., Briguglio, M., Marazziti, D., Mucci, F., Gambini, O., Tundo, A., Necci, R., Berardis, D., Galentino, R., Michele, S., D Addario, C., Servello, D., Albert, U., Maina, G., Ronchi, D., Altamura, A. C., Porta, M., Dell’Osso, Bernardo, Benatti, Beatrice, Hollander, Eric, Zohar, Joseph, Dell’Osso, Liliana, Fineberg, Naomi, Marcatili, M., Rigardetto, Sylvia, Briguglio, M., Marazziti, Donatella, Mucci, F., Gambini, Orsola, Tundo, Antonio, Necci, Roberta, De Berardis, Domenico, Galentino, R., De Michele, S., D’Addario, C., Servello, D., Albert, Umberto, Maina, Giuseppe, De Ronchi, Diana, Carlo Altamura, Alfredo, Porta, Mauro, Bernardo Dell’Osso, Beatrice Benatti, Eric Hollander, Joseph Zohar, Liliana Dell’Osso, Naomi Fineberg, M. Marcatili, Sylvia Rigardetto, M. Briguglio, Donatella Marazziti, F. Mucci, Orsola Gambini, Antonio Tundo, Roberta Necci, Domenico De Berardi, R. Galentino, S. De Michele, C. D’Addario, D. Servello, Umberto Albert, Giuseppe Maina, Diana De Ronchi, Alfredo Carlo Altamura, and Mauro Porta

Subjects
Obsessive-Compulsive Disorder • Tic Disorder • Obsessive-Compulsive Tic Disorder, Tic Disorder, Obsessive-Compulsive Disorder, mental disorders, Obsessive-Compulsive Tic Disorder
Abstract

In the DSM-5 a new “tic-related” specifier for obsessive compulsive disorder (OCD) has been introduced, highlighting the importance of an accurate characterization of patients suffering from obsessive-compulsive tic-related disorder (“OCTD”). In order to characterize OCTD from a socio-demographic and clinical perspective, the present multicenter study was carried out. The sample consists of 266 patients, divided in two groups with lifetime diagnoses of OCD and OCTD, respectively. OCTD vs OCD patients showed a significant male prevalence (68.5% vs 48.5%; p < .001), a higher rate of psychiatric comorbidities (69.4 vs 50%; p < .001) – mainly with neurodevelopmental disorders (24 vs 0%; p < .001), a lower education level and professional status (middle school diploma: 25 vs 7.6%; full-time job 44.4 vs 58%; p < .001). Moreover, OCTD vs OCD patients showed significantly earlier age of OCD and psychiatric comorbidity onsets (16.1 ± 10.8 vs 22.1 ± 9.5 years; p < .001, and 18.3 ± 12.8 vs 25.6 ± 9.4: p < .001, respectively). Patients with OCTD patients were treated mainly with antipsychotic and with a low rate of benzodiazepine (74.2 vs 38.2% and 20.2 vs 31.3%, respectively; p < .001). Finally, OCTD vs OCD patients showed higher rates of partial treatment response (58.1 vs 38%; p < .001), lower rates of current remission (35.5 vs 54.8%; p < .001) and higher rates of suicidal ideation (63.2 vs 41.7%; p < .001) and attempts (28.9 vs 8.3%; p < .001). Patients with OCTD report several unfavorable socio-demographic and clinical characteristics compared to OCD patients without a history of tic. Additional studies on larger sample are needed to further characterize OCTD patients from clinical and therapeutic perspectives.

29. Comparing the COVID-19-related PTSD symptoms between psychiatric patients and healthy subjects: an observational retrospective study from Northern Italy

Author

A Caldiroli, I Tagliabue, M Turco, E Capuzzi, A Fortunato, A Tringali, C Montana, L Maggioni, C Pellicioli, M Sibilla, M Marcatili, G Crespi, F Colmegna, M Buoli, M Clerici, Caldiroli, A, Tagliabue, I, Turco, M, Capuzzi, E, Fortunato, A, Tringali, A, Montana, C, Maggioni, L, Pellicioli, C, Sibilla, M, Marcatili, M, Crespi, G, Colmegna, F, Buoli, M, and Clerici, M

Subjects
IES-R, Psychiatry and Mental health, Clinical Psychology, COVID-19, PTSD, SARS-CoV-2 pandemic, Settore MED/25 - Psichiatria, Applied Psychology
Abstract

COVID-19 pandemic had a great impact on mental health, both in the general population and psychiatric patients. Little is known about the difference between these two populations in perceiving the pandemic as a traumatic event. The aim of the study was to compare psychiatric patients and healthy controls (HC) in terms of change over time of post-traumatic (PTSD) symptoms. Demographic and clinical variables were collected. Impact of Event Scale Revised (IES-R) scores were registered at T1 as lockdown period (March–April 2020) and T2 as restarting (May–June 2020). Descriptive analyses and linear regression models were performed. A total of 166 outpatients and 57 HC were recruited. Time (F=15.76; p T2 (p HC, although not statistically significant. The lockdown period was perceived as more traumatic than the reopening phase by both groups, with the exception of OCD patients, probably because of the clinical worsening associated with the urge of control against risks of contamination. Overall, HC reported more PTSD symptoms than psychiatric patients did, particularly SKZ ones. PD patients, in contrast, may be more vulnerable to PTSD symptoms probably as a result of poor coping skills. Together with OCD patients, subjects with PDs may need closer monitoring during the different phases of the pandemic. Trial Registration: ClinicalTrials.gov Identifier: NCT04694482.

Published
2023

30. Clinical Markers of Panic and Generalized Anxiety Disorder: Overlapping Symptoms, Different Course and Outcome

Author

Alice Caldiroli, Lia Colzani, Enrico Capuzzi, Cecilia Quitadamo, Davide La Tegola, Teresa Surace, Stefania Russo, Mauro Capetti, Silvia Leo, Agnese Tringali, Matteo Marcatili, Francesco Zanelli Quarantini, Fabrizia Colmegna, Antonios Dakanalis, Massimiliano Buoli, Massimo Clerici, Caldiroli, A, Colzani, L, Capuzzi, E, Quitadamo, C, La Tegola, D, Surace, T, Russo, S, Capetti, M, Leo, S, Tringali, A, Marcatili, M, Zanelli Quarantini, F, Colmegna, F, Dakanalis, A, Buoli, M, and Clerici, M

Subjects
generalized anxiety disorder, panic disorder, comorbidities, chronicity, outcome, anxiety disorders, comorbiditie, Medicine (miscellaneous), anxiety disorder
Abstract

Generalized Anxiety Disorder (GAD) and Panic Disorder (PD) share underlying neurobiological mechanisms and several clinical features which, with medical comorbidities, may increase misdiagnosis and delay proper treatment. The aim of the study was to evaluate the association between clinical/socio-demographic markers and GAD/PD diagnosis. Outpatients (N = 290) with PD or GAD were identified in mental health services in Monza and Milan (Italy). Descriptive analyses and a binary logistic regression model were performed. Post-onset psychiatric (p = 0.05) and medical (p = 0.02) multiple co-morbidities were associated with GAD; treatment with selective serotonin reuptake inhibitors (SSRIs) was associated with PD, while GAD diagnosis was associated with treatment with atypical antipsychotics or GABAergic drugs (p = 0.03), as well as psychodynamic psychotherapy (p < 0.01). Discontinuation of the last pharmacological treatment was associated with GAD diagnosis rather than the PD one (p = 0.02). GAD patients may have a worse prognosis than PD patients because of more frequent multiple co-morbidities, relapses and poorer treatment compliance. The different treatment approaches were consistent with the available literature, while the association between GAD and psychodynamic psychotherapy is an original finding of our study. Further studies on larger samples are necessary to better characterize clinical factors associated with GAD or PD.

Published
2023

31. The psychopathological impact of the SARS-CoV-2 epidemic on subjects suffering from different mental disorders: An observational retrospective study

Author

Alice Caldiroli, Enrico Capuzzi, Agnese Tringali, Ilaria Tagliabue, Marco Turco, Andrea Fortunato, Matteo Sibilla, Caterina Montana, Laura Maggioni, Cristian Pellicioli, Matteo Marcatili, Roberto Nava, Giovanna Crespi, Fabrizia Colmegna, Massimiliano Buoli, Massimo Clerici, Caldiroli, A, Capuzzi, E, Tringali, A, Tagliabue, I, Turco, M, Fortunato, A, Sibilla, M, Montana, C, Maggioni, L, Pellicioli, C, Marcatili, M, Nava, R, Crespi, G, Colmegna, F, Buoli, M, and Clerici, M

Subjects
Pandemic, Personality disorder, SARS-CoV-2, Mental Disorders, Psychotic symptom, COVID-19, Outpatient, Psychotic symptoms, Anxiety, Article, Obsessive-compulsive symptoms, Psychiatry and Mental health, Outpatients, Communicable Disease Control, Humans, Obsessive-compulsive symptom, Personality disorders, Pandemics, Biological Psychiatry, Retrospective Studies
Abstract

SARS-CoV-2 infection causes a pulmonary disease (COVID-19) which spread worldwide generating fear, anxiety, depression in the general population as well as among subjects affected by mental disorders. Little is known about which different psychopathological changes the pandemic caused among individuals affected by different psychiatric disorders, which represents the aim of the present study. Specific psychometric scales were administered at three time points: T0 as outbreak of pandemic, T1 as lockdown period, T2 as reopening. Descriptive analyses and linear regression models were performed. A total of 166 outpatients were included. Overall, psychometric scores showed a significant worsening at T1 with a mild improvement at T2. Only psychopathology in schizophrenia (SKZ) patients and obsessive-compulsive (OC) symptoms did not significantly improve at T2. Subjects affected by personality disorders (PDs) resulted to be more compromised in terms of general psychopathology than depressed and anxiety/OC ones, and showed more severe anxiety symptoms than SKZ patients. In conclusion, subjects affected by PDs require specific clinical attention during COVID-19 pandemic. Moreover, the worsening of SKZ and OC symptoms should be strictly monitored by clinicians, as these aspects did not improve with the end of lockdown measures. Further studies on larger samples are needed to confirm our results. ClinicalTrials.gov Identifier: NCT04694482.

Published
2022

32. Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review

Author

Antonios Dakanalis, Martina Capellazzi, Matteo Marcatili, Massimiliano Buoli, Alice Caldiroli, Massimo Clerici, Enrico Capuzzi, Fabrizia Colmegna, Ilaria Tagliabue, Francesco Mucci, Caldiroli, A, Capuzzi, E, Tagliabue, I, Capellazzi, M, Marcatili, M, Mucci, F, Colmegna, F, Clerici, M, Buoli, M, and Dakanalis, A

Subjects
Olanzapine, QH301-705.5, Cariprazine, Review, Lithium, Bioinformatics, Catalysis, Inorganic Chemistry, chemistry.chemical_compound, Depressive Disorder, Treatment-Resistant, augmentation, Medicine, Humans, Ziprasidone, Biology (General), Physical and Theoretical Chemistry, QD1-999, Molecular Biology, Spectroscopy, Brexpiprazole, psychopharmacology, Risperidone, business.industry, Organic Chemistry, General Medicine, medicine.disease, Antidepressive Agents, Buspirone, Computer Science Applications, Chemistry, Treatment‐resistant depression, chemistry, treatment-resistant depression, Quetiapine, Antidepressive Agents, Second-Generation, Aripiprazole, Anticonvulsants, Central Nervous System Stimulants, Ketamine, business, Treatment-resistant depression, medicine.drug
Abstract

Treatment resistant depression (TRD) is associated with poor outcomes, but a consensus is lacking in the literature regarding which compound represents the best pharmacological augmentation strategy to antidepressants (AD). In the present review, we identify the available literature regarding the pharmacological augmentation to AD in TRD. Research in the main psychiatric databases was performed (PubMed, ISI Web of Knowledge, PsychInfo). Only original articles in English with the main topic being pharmacological augmentation in TRD and presenting a precise definition of TRD were included. Aripiprazole and lithium were the most investigated molecules, and aripiprazole presented the strongest evidence of efficacy. Moreover, olanzapine, quetiapine, cariprazine, risperidone, and ziprasidone showed positive results but to a lesser extent. Brexpiprazole and intranasal esketamine need further study in real-world practice. Intravenous ketamine presented an evincible AD effect in the short-term. The efficacy of adjunctive ADs, antiepileptic drugs, psychostimulants, pramipexole, ropinirole, acetyl-salicylic acid, metyrapone, reserpine, testosterone, T3/T4, naltrexone, SAMe, and zinc cannot be precisely estimated in light of the limited available data. Studies on lamotrigine and pindolol reported negative results. According to our results, aripiprazole and lithium may be considered by clinicians as potential effective augmentative strategies in TRD, although the data regarding lithium are somewhat controversial. Reliable conclusions about the other molecules cannot be drawn. Further controlled comparative studies, standardized in terms of design, doses, and duration of the augmentative treatments, are needed to formulate definitive conclusions.

Published
2021

33. Prevention Plan for COVID-19 in a Psychiatric Long-term Care Rehabilitation Facility: An Italian Experience

Author

Prasad Wisidagamage Don, Matteo Marcatili, Fabrizia Colmegna, Roberto Nava, Massimo Clerici, Francesco Giuseppe Zanvit, Nava, R, Zanvit, F, Wisidagamage Don, P, Marcatili, M, Colmegna, F, and Clerici, M

Subjects
2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), business.industry, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), education.educational_degree, MEDLINE, Psychiatric rehabilitation, COVID-19, General Medicine, Plan (drawing), Psychiatric Rehabilitation, medicine.disease, Long-Term Care, Long-term care, Rehabilitation facility, Italy, medicine, Humans, Medical emergency, education, business
Published
2021

34. Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports

Author

Matteo Marcatili, Riccardo Borgonovo, Noemi Cimminiello, Ranieri Domenico Cornaggia, Giulia Casati, Cristian Pellicioli, Laura Maggioni, Federico Motta, Chiara Redaelli, Luisa Ledda, Federico Emanuele Pozzi, Michaela Krivosova, Jessica Pagano, Roberto Nava, Fabrizia Colmegna, Antonios Dakanalis, Alice Caldiroli, Enrico Capuzzi, Beatrice Benatti, Bernardo Dell’Osso, Francesca Bertola, Nicoletta Villa, Alberto Piperno, Silvia Ippolito, Ildebrando Appollonio, Carlo Sala, Luciano Conti, Massimo Clerici, Marcatili, M, Borgonovo, R, Cimminiello, N, Cornaggia, R, Casati, G, Pellicioli, C, Maggioni, L, Motta, F, Redaelli, C, Ledda, L, Pozzi, F, Krivosova, M, Pagano, J, Nava, R, Colmegna, F, Dakanalis, A, Caldiroli, A, Capuzzi, E, Benatti, B, Dell’Osso, B, Bertola, F, Villa, N, Piperno, A, Ippolito, S, Appollonio, I, Sala, C, Conti, L, and Clerici, M

Subjects
MED/26 - NEUROLOGIA, minocycline, esketamine, ketamine, major depressive disorder (MDD), difficult to treat depression (DTD), pharmacogenetic, MED/25 - PSICHIATRIA, Medicine (miscellaneous), pharmacogenetics, treatment resistant depression (TRD), Settore MED/25 - Psichiatria
Abstract

The advent of intra-nasal esketamine (ESK), one of the first so called fast-acting antidepressant, promises to revolutionize the management of treatment resistant depression (TRD). This NMDA receptor antagonist has proven to be rapidly effective in the short- and medium-term course of the illness, revealing its potential in targeting response in TRD. Although many TRD ESK responders are able to achieve remission, a considerable portion of them undergo a metamorphosis of their depression into different clinical presentations, characterized by instable responses and high recurrence rates that can be considered closer to the concept of Difficult to Treat Depression (DTD) than to TRD. The management of these DTD patients usually requires a further complex multidisciplinary approach and can benefit from the valuable contribution of new personalized medicine tools such as therapeutic drug monitoring and pharmacogenetics. Despite this, these patients usually come with long and complex previous treatments history and, often, advanced and sophisticated ongoing pharmacological schemes that can make the finding of new alternative options to face the current recurrences extremely challenging. In this paper, we describe two DTD patients—already receiving intranasal ESK but showing an instable course—who were clinically stabilized by the association with minocycline, a semisynthetic second-generation tetracycline with known and promising antidepressant properties.

Published
2022
Full Text
View/download PDF

35. Consultation psychiatry in COVID‐19 patients: Lopinavir/ritonavir interactions with main psychiatric drugs

Author

Antonios Dakanalis, Matteo Marcatili, Enrico Capuzzi, Ester di Giacomo, Alberto Stefana, Emiliano D'Amico, Massimo Clerici, Fabrizia Colmegna, Marcatili, M, Stefana, A, Colmegna, F, di Giacomo, E, D'Amico, E, Capuzzi, E, Dakanalis, A, and Clerici, M

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Viral Protease Inhibitors, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), MEDLINE, Clinical Neurology, Lopinavir/ritonavir, Lopinavir, medicine, Humans, Psychiatric drugs, Drug Interactions, Psychiatry, Letters to the Editor, Letter to the Editor, Referral and Consultation, Psychotropic Drugs, Ritonavir, business.industry, General Neuroscience, Psychotropic Drug, COVID-19, General Medicine, COVID-19 Drug Treatment, Psychiatry and Mental health, Long QT Syndrome, Consultation psychiatry, Drug Interaction, Neurology, Viral Protease Inhibitor, Neurology (clinical), business, Hypericum, Human, medicine.drug
Published
2021

36. Human induced pluripotent stem cells technology in treatment resistant depression: novel strategies and opportunities to unravel ketamine's fast-acting antidepressant mechanisms

Author

Fabrizia Colmegna, Beatrice Benatti, Carlo Sala, Massimo Clerici, Luciano Conti, Bernardo Dell'Osso, Matteo Marcatili, Armando D'Agostino, Antonios Dakanalis, Orsola Gambini, Marcatili, M, Sala, C, Dakanalis, A, Colmegna, F, D'Agostino, A, Gambini, O, Dell'Osso, B, Benatti, B, Conti, L, and Clerici, M

Subjects
0301 basic medicine, induced pluripotent stem cell, ketamine, lcsh:RC435-571, induced pluripotent stem cells, drug response, glutamate N-methyl-d-aspartate, in vitro model, major depressive disorder, neurons, treatment-resistant depression, Review, 03 medical and health sciences, 0302 clinical medicine, Genome editing, lcsh:Psychiatry, medicine, Ketamine, Human Induced Pluripotent Stem Cells, Induced pluripotent stem cell, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Drug discovery, business.industry, lcsh:RM1-950, Novel Strategies for the Treatment of Depression, medicine.disease, neuron, lcsh:Therapeutics. Pharmacology, 030104 developmental biology, Major depressive disorder, Antidepressant, Psychology (miscellaneous), business, Treatment-resistant depression, Neuroscience, 030217 neurology & neurosurgery, medicine.drug
Abstract

Approximately 30% of Major Depressive Disorder (MDD) patients develop treatment-resistant depression (TRD). Among the different causes that make TRD so challenging in both clinical and research contexts, major roles are played by the inadequate understanding of MDD pathophysiology and the limitations of current pharmacological treatments. Nevertheless, the field of psychiatry is facing exciting times. Combined with recent advances in genome editing techniques, human induced pluripotent stem cell (hiPSC) technology is offering novel and unique opportunities in both disease modelling and drug discovery. This technology has allowed innovative disease-relevant patient-specific in vitro models to be set up for many psychiatric disorders. Such models hold great potential in enhancing our understanding of MDD pathophysiology and overcoming many of the well-known practical limitations inherent to animal and post-mortem models. Moreover, the field is approaching the advent of (es)ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, claimed as one of the first and exemplary agents with rapid (in hours) antidepressant effects, even in TRD patients. Although ketamine seems poised to transform the treatment of depression, its exact mechanisms of action are still unclear but greatly demanded, as the resulting knowledge may provide a model to understand the mechanisms behind rapid-acting antidepressants, which may lead to the discovery of novel compounds for the treatment of depression. After reviewing insights into ketamine’s mechanisms of action (derived from preclinical animal studies) and depicting the current state of the art of hiPSC technology below, we will consider the implementation of an hiPSC technology-based TRD model for the study of ketamine’s fast acting antidepressant mechanisms of action.

Published
2020

37. Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review

Author

Matteo Marcatili, Martina Capellazzi, Alice Caldiroli, Enrico Capuzzi, Ilaria Tagliabue, Massimiliano Buoli, Antonios Dakanalis, Fabrizia Colmegna, Massimo Clerici, Capuzzi, E, Caldiroli, A, Capellazzi, M, Tagliabue, I, Marcatili, M, Colmegna, F, Clerici, M, Buoli, M, and Dakanalis, A

Subjects
Oncology, medicine.medical_specialty, QH301-705.5, Esketamine, Review, Relapse prevention, Catalysis, Inorganic Chemistry, Depressive Disorder, Treatment-Resistant, Internal medicine, Secondary Prevention, medicine, Humans, Biology (General), Physical and Theoretical Chemistry, QD1-999, Molecular Biology, Administration, Intranasal, Spectroscopy, Depression (differential diagnoses), clinical trials, Depressive Disorder, Major, business.industry, Organic Chemistry, Continuation, General Medicine, medicine.disease, Antidepressive Agents, Computer Science Applications, Discontinuation, Clinical trial, Chemistry, Systematic review, Antidepressant, Ketamine, Nasal administration, Treatment-resistant depression, business, medicine.drug
Abstract

Esketamine (ESK) has been approved as a rapid-acting intranasal treatment for treatment-resistant depression (TRD). Although existing studies have investigated the efficacy of ESK in the 4-week induction phase, our knowledge about long-term ESK efficacy remains poor. The aim of this systematic review was to summarize the available data on long-term ESK efficacy for TRD. A systematic search was performed including articles in English, up to 31 March 2021. The search found 7 relevant studies, involving 1024 adult TRD patients. Continuing treatment with ESK after the 4-week induction phase may be associated with stable efficacy in relapse prevention among TRD patients. Conversely, the long-term antidepressant effectiveness upon discontinuation of ESK might be limited, although data from three studies had a moderate to high risk of bias. Overall, the results on the effectiveness of this compound in the long term are mixed. According to our findings, ESK treatment should be continued following the induction phase to reach a stable efficacy in relapse prevention, while the long-term antidepressant and anti-suicidal effects of ESK after discontinuation are inconsistent. Currently, the level of proof of ESK efficacy in long-term TRD treatment remains low and more RCTs with larger sample sizes and active comparators are needed.

Published
2021
Full Text
View/download PDF

38. Esketamine Treatment Trajectory of Patients with Treatment-Resistant Depression in the Mid and Long-Term Run: Data from REAL-ESK Study Group.

Author

Rosso G, d'Andrea G, Barlati S, Di Nicola M, Andriola I, Marcatili M, Martiadis V, Olivola M, Di Mauro S, Di Salvo G, De Fazio P, Clerici M, Dell'Osso BM, Vita A, Di Lorenzo G, Pettorruso M, Martinotti G, and Maina G

Subjects
Humans, Male, Female, Middle Aged, Adult, Retrospective Studies, Antidepressive Agents therapeutic use, Treatment Outcome, Aged, Italy, Follow-Up Studies, Administration, Intranasal, Nasal Sprays, Ketamine therapeutic use, Ketamine administration & dosage, Depressive Disorder, Treatment-Resistant drug therapy
Abstract

Introduction/objective: Data on long-term treatment with Esketamine Nasal Spray (ESKNS) in real-world patients with treatment resistant depression (TRD) is scarce. The primary aim of the study is to evaluate the effectiveness and tolerability of ESK-NS treatment at 6 and 12-month follow-ups., Methods: This is part of an observational, retrospective, multicentric Italian study (REAL-ESK study). Subjects for the present study underwent psychiatric assessments after 6 and 12 months from the start of ESK-NS treatment. Repeated measures analysis of variance (ANOVA) was used to assess changes in continuous variables, such as scores on psychometric scales from baseline to follow-up time points., Results: Of 63 patients who maintained ESK-NS treatment for at least 6 months, 48 were responders or remitters (76.2%). Among 15 non-responders at 6 months, 4 significantly improved at 12-month follow-up. At least one side effect was reported by 71.8% of subjects with a 6-month follow-up assessment. An overall reduction of side effects was noticed as treatment progressed (42% of patients who continued the treatment reported side effects at 12 months). The most common side effects were sedation (31.7%) and dissociation (28.6%) during ESK-NS sessions. Only 2 patients discontinued ESK-NS for tolerability reasons., Conclusion: The results support the effectiveness and safety of esketamine in the mid and long-term treatment of TRD patients. The late clinical response of a subgroup of patients represents a novel finding. Data needs to be confirmed in larger samples and longer observation periods., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)

Published
2025
Full Text
View/download PDF

39. Hoof wall masses removal in 30 standing sedated horses: Surgical technique, postoperative complications and long-term outcome.

Author

Ross C, White JM, Hibner-Szaltys M, Stephenson RS, Withers JM, and Marcatili M

Subjects
Animals, Horses, Retrospective Studies, Female, Male, Hoof and Claw surgery, Foot Diseases veterinary, Foot Diseases surgery, Anesthesia, Local veterinary, Treatment Outcome, Lameness, Animal, Horse Diseases surgery, Postoperative Complications veterinary
Abstract

Objective: To describe the surgical technique for removal of hoof wall masses in horses under standing sedation (SS) and local anesthesia (LA), and to report complications and long-term outcome following surgery., Study Design: Observational retrospective study., Animals: Client-owned horses (n = 30)., Methods: Horses undergoing keratoma removal under SS and LA in a single equine hospital between August 2016 and July 2023 were included in the study. Signalment, affected foot, history of lameness and/or foot abscesses, degree of lameness on admission, imaging findings (radiography and magnetic resonance imaging [MRI] when available), location of the mass, surgical technique, remedial farriery, postoperative care, complications and outcome were recorded. Long-term follow-up information was obtained by telephone questionnaire., Results: A total of 30 horses met the inclusion criteria. Duration of lameness ranged from 1 to 289 days (mean 90 days). The degree of lameness varied from absent to grade 4/5 (AAEP) (mean grade 3/5). All horses underwent preoperative radiographic examination and 14/30 underwent MRI. All horses underwent partial hoof wall resection. The surgery was performed safely in all cases. Postoperative complications included marked lameness in the early postoperative period in 3/30 horses and exuberant granulation tissue formation in 2/30 horses. Long-term (>6 months) follow-up information was available for 28 horses, and 26/28 horses returned to previous levels of exercise. Recurrence was suspected in 1/30 horses., Conclusions: The complication rate was lower than previously reported for keratoma removal under general anesthesia (GA)., Clinical Significance: Removal of hoof wall masses under SS and LA can be considered as an alternative to removal under GA., (© 2024 American College of Veterinary Surgeons.)

Published
2025
Full Text
View/download PDF

40. Assessing the Fear of Covid-19 in Psychiatric Patients: Results from an Italian Multicentric Study.

Author

Nava R, Benatti B, Girone N, Macellaro M, Pellicioli C, Maggioni L, Marcatili M, Dell'Osso B, and Clerici M

Abstract

Objective: Even though the COVID-19 emergency has concluded, its consequences are still relevant. Recent evidence suggests that a significant proportion of individuals experience persistent symptoms long after the initial infection has resolved, classified as "Long COVID" condition. Fear of COVID-19 increases anxiety and stress levels in healthy individuals and exacerbates the symptoms of those with pre-existing psychiatric disorders; therefore understanding the impact of the pandemic on psychiatric disorders remains of utmost importance. The present study aimed at assessing the prevalence and predictive factors of fear of COVID-19 in a sample of patients with different psychiatric conditions., Method: A sample of 269 psychiatric patients were recruited from two different tertiary clinics in Italy and assessed with the Fear of COVID-19 Scale (FCV-19S). In order to compare patients with a significant fear of COVID-19 or without (Fear+ vs. Fear-) and to identify the main features in terms of clinical dimension, exploratory and predictive analysis were performed., Results: Female gender, age at illness onset, and insight levels emerged as positive predictors of FCV-19S. Conversely, current substance abuse emerged as a negative predictor of fear levels. Moreover, significantly lower FCV-19S scores were observed in patients with a diagnosis of schizophrenia spectrum disorders., Conclusions: Specific sociodemographic and clinical factors predicted higher levels of fear of COVID-19 in psychiatric patients. Further studies are warranted to determine the potential long-term consequences of the COVID-19 impact on mental health., Competing Interests: Competing interests: None., (© 2024 Giovanni Fioriti Editore s.r.l.)

Published
2024
Full Text
View/download PDF

41. Effect of breed, obturator type and surgical experience on tenoscopic portal creation into the digital flexor tendon sheath in horses.

Author

White JM, Hibner-Szaltys M, Duz M, Withers JM, and Marcatili M

Subjects
Animals, Horses, Tendons surgery, Tendons anatomy & histology, Prospective Studies, Forelimb surgery, Endoscopy veterinary, Endoscopy methods, Female, Male, Tendon Injuries veterinary, Tendon Injuries surgery, Cadaver
Abstract

Objective: To determine the influence of breed (cob [CB] and non-cob [NC]), obturator type and surgical experience on the number of attempts, time taken and iatrogenic damage (ID) created when entering the digital flexor tendon sheath (DFTS) tenoscopically., Study Design: Prospective experimental cadaveric study., Animals: A total of 104 cadaver limbs., Methods: An equal number of randomly selected CB and NC limbs were operated using a conical obturator (OB) or a switching stick (SS) by one boarded (BS) and one resident surgeon (RS). Skin measurements, number of attempts and time taken to enter the DFTS were recorded. The DFTS was endoscopically examined and then dissected to record ID and cumulative ID calculated., Results: Mean CB skin thickness (8.4 mm) was nearly twice that of NC limbs (4.5 mm) (p < .001). Mean DFTS entry took longer in CB limbs (133 s) compared to NC limbs (112 s) (p = .02). BS mean entry time in CB limbs was 115 s compared to 46 s in NC limbs (p < .001). Cumulative ID was greater in CB limbs (25 of 52 limbs with ID) compared to NC limbs (14 of 52 limbs with ID) (p = .04). No difference was noted between obturators. Surgical experience reduced attempts and time entering the DFTS., Conclusion: Surgeons take longer to enter DFTS in CB limbs and more cumulative ID is created, regardless of obturator type used., Clinical Significance: Skin thickness is a major determinant of time taken to enter the DFTS and increases the risk of ID. Awareness of the challenges in CB limbs is important., (© 2024 American College of Veterinary Surgeons.)

Published
2024
Full Text
View/download PDF

42. Fetal rhabdomyoma in a Thoroughbred filly.

Author

Rapezzano G, Foote A, Petrini F, Pereira R, and Marcatili M

Subjects
Animals, Horses, Female, Animals, Newborn, Rhabdomyoma veterinary, Rhabdomyoma surgery, Rhabdomyoma diagnosis, Rhabdomyoma pathology, Rhabdomyoma diagnostic imaging, Horse Diseases surgery, Horse Diseases diagnosis, Horse Diseases pathology, Horse Diseases congenital
Abstract

A newborn Thoroughbred filly presented with a large mass located on the ventro-rostral aspect of the mandible. The mass was surgically removed under general anaesthesia. Upon gross examination, the mass was well circumscribed with a heterogeneous lobulated appearance. The results of histopathology and immunohistochemistry were consistent with a diagnosis of congenital fetal rhabdomyoma. On follow-up at six months post-surgical excision, no abnormalities were noted on clinical examination., (© 2024 The Author(s). Veterinary Medicine and Science published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

43. Outcome of tenoscopically guided palmar/plantar annular ligament desmotomy for the treatment of palmar/plantar annular ligament constriction without concurrent intrathecal soft-tissue injury in a UK horse population.

Author

Wood AD, Parker RA, Marcatili M, Anderson J, Robinson N, and Stack JD

Subjects
Animals, Horses, Retrospective Studies, Female, Male, United Kingdom, Treatment Outcome, Endoscopy veterinary, Endoscopy methods, Ligaments surgery, Ligaments injuries, Cohort Studies, Tenosynovitis veterinary, Tenosynovitis surgery, Soft Tissue Injuries veterinary, Soft Tissue Injuries surgery, Horse Diseases surgery
Abstract

Objective: To determine the outcome of tenoscopically guided palmar/plantar annular ligament (PAL) desmotomy to treat PAL constriction without concurrent intrathecal soft-tissue injury, notably of the digital flexor tendons and manica flexoria., Study Design: Retrospective multicenter cohort study., Animals: Sixty-five horses., Methods: Horses from four UK equine hospitals, with digital flexor tendon sheath (DFTS) tenosynovitis, which underwent tenoscopically guided PAL desmotomy for treatment of PAL constriction between 2017 and 2022 were included. All horses had lameness isolated to the DFTS/PAL, and PAL constriction was diagnosed tenoscopically when there was difficulty maneuvering the endoscope into or through the fetlock canal. Horses with tearing of the digital flexor tendons and/or manica flexoria, or any other intrathecal pathology, were excluded. Follow up was via structured telephone questionnaire., Results: Follow up (median 25 months) was available for 61 horses with cobs and ponies predominating. Forty-two returned to their previous level of work, or a higher level, postoperatively and 50 owners were satisfied with the outcome of surgery. Eleven horses returned to lower level exercise, and six were retired/euthanized as they did not regain soundness. Fifty-two horses achieved soundness (median 3 months postoperatively)., Conclusion: Tenoscopically guided PAL desmotomy for the treatment of PAL constriction in the absence of intrathecal soft tissue injury had a good prognosis for return to previous levels of exercise in a UK horse population., Clinical Significance: The prognosis for horses undergoing tenoscopically guided PAL desmotomy to treat PAL constriction in the absence of intrathecal injury is better than previously described. Cobs and ponies seem to be predisposed to PAL constriction in agreement with the previous literature., (© 2024 The Author(s). Veterinary Surgery published by Wiley Periodicals LLC on behalf of American College of Veterinary Surgeons.)

Published
2024
Full Text
View/download PDF

44. Evaluation of peritoneal l-lactate concentration in horses in the early post-partum period.

Author

Rapezzano G, Marcatili M, Stephenson R, Pereira R, Hallowell G, and Duz M

Subjects
Animals, Horses, Female, Retrospective Studies, Abdominal Pain veterinary, Lactic Acid, Postpartum Period
Abstract

Background: Peritoneal fluid lactate concentration is an important diagnostic tool in horses with abdominal pain. Information on peritoneal lactate concentrations is lacking following parturition in the mare., Objectives: To compare blood and peritoneal lactate concentrations in a population of mares within 36 h post-partum, report a normal reference range and identify any impact of retained foetal membranes (RFMs)., Methods: This is a retrospective study evaluating healthy mares from which blood and peritoneal samples had been obtained within 36 h of parturition. Exclusion criteria included signs of abdominal pain within this period. Data was interrogated for normality using a Shapiro-Wilk test. Wilcoxon signed-rank test and Bland-Altman analysis were used to compare blood and peritoneal lactate concentrations. Linear regression was used to compare age and breed data with peritoneal lactate concentrations. Significance was defined as p < 0.05., Results: Forty mares met the inclusion criteria. Mean age was 12.6 ± 4.1 years, and most mares were multiparous (65%). Peritoneal lactate ((1.2 (IQR = 0.9-1.6) mmol/L) was increased compared to blood lactate concentration (0.7 (IQR = 0-1.1)mmol/L; p < 0.001). Plasma total protein (TP) concentrations were 68 (IQR = 64-74) g/L and peritoneal protein concentrations 8 (IQR = 4-9.7) g/L. Six mares developed RFM. The median fold-increase in peritoneal lactate concentration compared to blood lactate concentration was 0.9 (IQR: 0.01-1.7; range: 0-2.5). The reference range for peritoneal fluid lactate concentration was 0-2.5 mmol/L., Conclusion: Peritoneal lactate concentrations in healthy post-partum mares remained within the normal reference range and were not influenced by RFM or parturition. Increased peritoneal lactate in this group warrants further investigation., (© 2024 The Authors. Veterinary Medicine and Science published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

45. Proof-of-concept evidence for high-density EEG investigation of sleep slow wave traveling in First-Episode Psychosis.

Author

Castelnovo A, Casetta C, Cavallotti S, Marcatili M, Del Fabro L, Canevini MP, Sarasso S, and D'Agostino A

Subjects
Humans, Electroencephalography, Sleep physiology, Clozapine, Psychotic Disorders, Schizophrenia drug therapy
Abstract

Schizophrenia is thought to reflect aberrant connectivity within cortico-cortical and reentrant thalamo-cortical loops, which physiologically integrate and coordinate the function of multiple cortical and subcortical structures. Despite extensive research, reliable biomarkers of such "dys-connectivity" remain to be identified at the onset of psychosis, and before exposure to antipsychotic drugs. Because slow waves travel across the brain during sleep, they represent an ideal paradigm to study pathological conditions affecting brain connectivity. Here, we provide proof-of-concept evidence for a novel approach to investigate slow wave traveling properties in First-Episode Psychosis (FEP) with high-density electroencephalography (EEG). Whole-night sleep recordings of 5 drug-naïve FEP and 5 age- and gender-matched healthy control subjects were obtained with a 256-channel EEG system. One patient was re-recorded after 6 months and 3 years of continuous clozapine treatment. Slow wave detection and traveling properties were obtained with an open-source toolbox. Slow wave density and slow wave traveled distance (measured as the line of longest displacement) were significantly lower in patients (p < 0.05). In the patient who was tested longitudinally during effective clozapine treatment, slow wave density normalized, while traveling distance only partially recovered. These preliminary findings suggest that slow wave traveling could be employed in larger samples to detect cortical "dys-connectivity" at psychosis onset., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

46. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.

Author

d'Andrea G, Pettorruso M, Di Lorenzo G, Rhee TG, Chiappini S, Carullo R, Barlati S, Zanardi R, Rosso G, Di Nicola M, Andriola I, Marcatili M, Clerici M, Dell'Osso BM, Sensi SL, Mansur RB, Rosenblat JD, Martinotti G, and McIntyre RS

Subjects
Humans, Canada, Antidepressive Agents adverse effects, Drug Therapy, Combination, Depression, Treatment Outcome, Ketamine therapeutic use, Depressive Disorder, Treatment-Resistant drug therapy
Abstract

Introduction: Intravenous ketamine (KET-IV) and intranasal esketamine (ESK-NS) are effective in the acute treatment of Treatment-Resistant Depression (TRD). Studies comparing KET-IV and ESK-NS concerning their action, safety, and tolerability are currently lacking., Materials and Methods: We combined patients' data from two unipolar TRD cohorts that received KET-IV (n = 171) at the Canadian Rapid Treatment Center of Excellence in Toronto, Canada, or ESK-NS (n = 140) at several TRD clinics in Italy. The Quick Inventory for Depression Symptomatology-Self-Report-16/QIDS-SR16 in the KET-IV group and Montgomery-Åsberg Depression Rating Scale/MADRS in the ESK-NS group measured depressive symptoms at baseline (T0) and after the acute treatment phase (T1) (i.e., four infusions of KET-IV and eight administrations of ESK-NS). As different scales were used, the primary outcome was to compare the improvement in depression severity in the two cohorts by measuring effect sizes, response and remission rates. Finally, we compare side effects and discontinuation rates., Results: At T1, KET-IV and ESK-NS significantly reduced depressive symptoms (respectively: QIDS-SR16 mean reduction = 5.65, p < 0.001; MADRS mean reduction = 11.41, p = 0.025). KET-IV showed larger effect sizes compared to ESK-NS (1.666 vs. 1.244). KET-IV had higher response rates (36 % vs. 25 %; p = 0.042) but not superior remission rates (13 % vs. 12 %; p = 0.845) than ESK-NS at T1. Despite more reported side effects, KET-IV did not cause more discontinuations for adverse events (4.6 % vs. 2.12 %; p = 0.228) than ESK-NS., Conclusion: KET-IV showed a higher short-term antidepressant effect, whereas ESK-NS exhibited lower side effects. Both were generally well tolerated. Future head-to-head studies should consider the long-term efficacy of these treatments., Competing Interests: Declaration of competing interest Dr. Taeho Greg Rhee was supported in part by the National Institute on Aging (NIA) (#R21AG070666; R21AG078972), National Institute of Mental Health (#R21MH117438), National Institute on Drug Abuse (#R21DA057540) and Institute for Collaboration on Health, Intervention, and Policy (InCHIP) of the University of Connecticut. Dr. Rhee serves as a review committee member for Patient-Centered Outcomes Research Institute (PCORI) and Substance Abuse and Mental Health Services Administration (SAMHSA) and has received honoraria payments from PCORI and SAMHSA. Dr. Rhee has also served as a stakeholder/consultant for PCORI and received consulting fees from PCORI. Dr. Rhee serves as an advisory committee member for International Alliance of Mental Health Research Funders (IAMHRF). Dr. Rhee is currently a co-Editor-in-Chief of Mental Health Science and has received honorarium payments annually from the publisher, John Wiley & Sons, Inc. Dr. Giorgio Di Lorenzo has been a speaker and/or a consultant for Angelini, FB-Health, Janssen-Cilag, Livanova, Lundbeck, Neuraxpharm, Otsuka, and Recordati. Dr. Raffaella Zanardi has been a consultant/speaker for Baldacci and Italfarmaco. Dr. Gianluca Rosso has been a speaker and/or consultant from Angelini, Janssen, Lundbeck, Otsuka, Viatris. Dr. Ileana Andriola was a speaker at Janssen sponsored conference. Dr. Bernardo Maria Dell'Osso has received lecture honoraria from Angelini, Lundbeck, Janssen, Pfizer, Neuraxpharm, Arcapharma, and Livanova. Dr. Rosenblat is the medical director of the Braxia Scientific Corp, which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Dr. Giovanni Martinotti has been a consultant and/or a speaker and/or has received research grants from Angelini, Doc Generici, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Servier, and Recordati. Dr. Roger McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Atai Life Sciences. Dr. Roger McIntyre is the CEO of Braxia Scientific Corp. The remaining authors declare that the research was conducted without any commercial or financial relationship that could be construed as a potential conflict of interest., (Copyright © 2023. Published by Elsevier B.V.)

Published
2024
Full Text
View/download PDF

47. Perspective on the role of pharmacogenetic testing in mental health care in Slovakia.

Author

Krivosova M, Hutka P, Kusnierova S, Macekova Z, Maggioni L, Marcatili M, Clerici M, and Mokry J

Subjects
Humans, Slovakia, Surveys and Questionnaires, Male, Female, Adult, Attitude of Health Personnel, Middle Aged, Pharmacogenomic Testing, Mental Disorders drug therapy, Mental Disorders genetics, Mental Disorders diagnosis
Abstract

Background: The pathophysiology of mental illnesses is not fully understood, leading to insufficient remission, frequent adverse drug reactions, and treatment resistance. Pharmacogenetic (PGx) testing, a personalized approach recently adopted also in psychiatry, can guide effective drug therapy and minimize side effects. The objective of this study was to determine the perspective of Slovak clinicians regarding the integration of PGx testing in psychiatric clinical practice., Methods: Questionnaires covering various aspects such as prior experience with PGx testing, self-perceived competence, perceived utility, potential risks and challenges were distributed directly to attendees at two psychiatric conferences held in Slovakia in 2023 and their responses were statistically analysed., Results: Out of 54 respondents, only 7.4% had previous experience with PGx in clinical practice. The most clinicians felt that they should possess the skills to apply PGx testing in psychiatric clinical practice and were enthusiastic about increasing their expertise. They found PGx useful in medication selection, adverse effect management, and treatment-resistant depression. The primary concerns centered around the lack of well-defined guidelines and the financial considerations linked to the testing., Conclusions: Considering the participants' interest in PGx and its integration into clinical practice, educational programmes based on recommendations, guidelines, and convincing evidence could be organized (Tab. 4, Ref. 30). Text in PDF www.elis.sk Keywords: pharmacogenetics, pharmacogenomics, psychiatry, personalized treatment, Slovakia, perspective.

Published
2024
Full Text
View/download PDF

48. Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).

Author

Pettorruso M, Guidotti R, d'Andrea G, De Risio L, D'Andrea A, Chiappini S, Carullo R, Barlati S, Zanardi R, Rosso G, De Filippis S, Di Nicola M, Andriola I, Marcatili M, Nicolò G, Martiadis V, Bassetti R, Nucifora D, De Fazio P, Rosenblat JD, Clerici M, Maria Dell'Osso B, Vita A, Marzetti L, Sensi SL, Di Lorenzo G, McIntyre RS, and Martinotti G

Subjects
Humans, Retrospective Studies, Depression drug therapy, Reproducibility of Results, Machine Learning, Treatment Outcome, Antidepressive Agents therapeutic use, Depressive Disorder, Treatment-Resistant drug therapy, Depressive Disorder, Treatment-Resistant diagnosis
Abstract

Treatment-resistant depression (TRD) represents a severe clinical condition with high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD by EMA and FDA, but data about predictors of response are still lacking. Thus, a tool that can predict the individual patients' probability of response to ESK-NS is needed. This study investigates sociodemographic and clinical features predicting responses to ESK-NS in TRD patients using machine learning techniques. In a retrospective, multicentric, real-world study involving 149 TRD subjects, psychometric data (Montgomery-Asberg-Depression-Rating-Scale/MADRS, Brief-Psychiatric-Rating-Scale/BPRS, Hamilton-Anxiety-Rating-Scale/HAM-A, Hamilton-Depression-Rating-Scale/HAMD-17) were collected at baseline and at one month/T1 and three months/T2 post-treatment initiation. We trained three different random forest classifiers, able to predict responses to ESK-NS with accuracies of 68.53% at T1 and 66.26% at T2 and remission at T2 with 68.60% of accuracy. Features like severe anhedonia, anxious distress, mixed symptoms as well as bipolarity were found to positively predict response and remission. At the same time, benzodiazepine usage and depression severity were linked to delayed responses. Despite some limitations (i.e., retrospective study, lack of biomarkers, lack of a correct interrater-reliability across the different centers), these findings suggest the potential of machine learning in personalized intervention for TRD., Competing Interests: Declaration of Competing Interest The remaining authors declare that the research was conducted without any commercial or financial relationship that could be construed as a potential conflict of interest., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)

Published
2023
Full Text
View/download PDF

49. Negative-Pressure Wound Therapy (NPWT) in Horses: A Scoping Review.

Author

Cantatore F, Pagliara E, Marcatili M, and Bertuglia A

Abstract

Obtaining a healthy wound environment that is conductive to healing in horses can be challenging. Negative-pressure wound therapy (NPWT) has been employed in humans to enhance wound healing for decades. The existing evidence for the effectiveness of NPWT remains uncertain in equine medicine. The aim of this review is to investigate NPWT applications and benefits in horses. A scoping review was performed according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines for scoping reviews on three databases (PubMed, Web of Science-Thompson Reuters, and Wiley Online Library). Twenty-four manuscripts were considered. After removing duplicates, 17 papers underwent abstract screening. Of these, 16 + 1 (cited by others) were evaluated for eligibility according to PICOs, including no case reports/retrospective studies, four original articles, and three reviews. Fifteen manuscripts met the inclusion criteria. The focus of the articles was wound management; they included three reports of wounds communicating with synovial structures. Traumatic wounds and surgical-site infections are indications for NPWT. NPWT presents several advantages and few complications making it an attractive alternative to conventional wound management. However, randomized controlled trials should be performed to quantify the benefits and establish precise protocols in horses.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results